CYTOSTATIC DRUGS IN THE TREATMENT OF SECONDARY DISEASE FOLLOWING HOMOLOGOUS BONE MARROW TRANSPLANTATION: EXTRAPOLATION FROM THE MOUSE TO THE PRIMATE*